

chain nodes :

7 8 9 13

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

10

chain bonds :

2-8 4-7 8-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 8-9

exact bonds :

2-8


isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS 11:CLASS  
13:CLASS 14:CLASS

=>  
Uploading C:\Program Files\Stnexp\Queries\10586501.str



chain nodes :

7 8 9 13

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

10

chain bonds :

2-8 4-7 8-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 8-9

exact bonds :

2-8

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS


11:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss sam
SAMPLE SEARCH INITIATED 17:03:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      649 TO ITERATE

100.0% PROCESSED      649 ITERATIONS          11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:    11452 TO    14508
PROJECTED ANSWERS:        22 TO      418

L2      11 SEA SSS SAM L1

=> => s 11 sss ful
FULL SEARCH INITIATED 17:06:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12660 TO ITERATE

100.0% PROCESSED      12660 ITERATIONS         214 ANSWERS
SEARCH TIME: 00.00.01

L3      214 SEA SSS FUL L1


=> => s 13
L4      5 L3

=> d 14 1-5 bib,ab,hitstr
```

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 2006:1252758 CAPLUS  
 DN 146:45528  
 TI Use of cyanopyrimidines for the treatment of cardiovascular diseases and their preparation  
 IN Hendrix, Martin; Wunder, Frank; Tersteegen, Adrian; Stasch, Johannes-Peter  
 PA Bayer Healthcare A.-G., Germany  
 SO PCT Int. Appl., 105pp.  
 CODEN: PIXXD2

DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125554	A	20061130	WO 2006-EP4639	20060517
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	DE 102005024494	A1	20061130	DE 2005-102005024494	20050527
	EP 1890702	A1	20080227	EP 2006-742947	20060517
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	DE 2005-102005024494	A	20050527		
	WO 2006-EP4639	W	20060517		
OS	CASREACT 146:45528; MARPAT 146:45528				
AB	The invention relates to the use of cyanopyrimidines of formula I for producing medicaments utilized for the treatment of cardiovascular diseases. Compds. of formula I wherein A is (un)substituted C1-8 alkyl, (un)substituted C3-8 cycloalkyl, (un)substituted tetrahydrofuryl and (un)substituted tetrahydropyran; B is (un)substituted Ph and (un)substituted heteroaryl; and their pharmaceutically acceptable salts, solvates, solvated salts thereof are claimed. Example compound II was prepared by substitution of 2-(3,4-dichlorobenzyl)-4-(methylsulfanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile with piperidine. All the invention compds. were evaluated for their phosphodiesterase inhibitory activity. These compds. may be useful in the treatment of cardiovascular diseases.				
IT	860813-66-7P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(drug candidate and intermediate; preparation of cyanopyrimidines useful in the treatment of cardiovascular diseases)				
RN	860813-66-7 CAPLUS				
CN	5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)				



IT	860813-32-7P	860813-33-8P	860813-34-9P
	860813-35-0P	860813-36-1P	860813-37-2P
	860813-38-3P	860813-39-4P	860813-40-7P
	860813-41-8P	860813-42-9P	860813-43-0P
	860813-44-1P	860813-45-2P	860813-46-3P
	860813-47-4P	860813-49-6P	860813-50-9P
	860813-51-0P	860813-52-1P	860813-53-2P
	860813-54-3P	860813-55-4P	860813-56-5P
	860813-57-6P	860813-58-7P	860813-59-8P
	860813-60-1P	860813-61-2P	860813-62-3P
	860813-63-4P	860813-64-5P	860813-65-6P
	860813-67-8P	860813-68-9P	860813-69-0P
	860813-70-3P	860813-71-4P	860813-72-5P
	860813-73-6P	860813-74-7P	860813-75-8P
	860813-76-9P	860813-77-0P	860813-78-1P
	860813-82-7P	860813-83-8P	860813-84-9P
	860813-85-0P	860813-86-1P	860813-87-2P
	860813-88-3P	860813-89-4P	860813-90-7P
	860813-91-8P	860813-92-9P	860813-93-0P
	860813-94-1P	860813-95-2P	860813-96-3P
	860813-97-4P	860813-98-5P	860813-99-6P
	860814-00-2P	860814-01-3P	860814-02-4P
	860814-03-5P	860814-04-6P	860814-05-7P
	860814-06-8P	860814-07-9P	860814-08-0P
	860814-10-4P	860814-12-6P	860814-13-7P
	860814-14-8P	860814-15-9P	860814-16-0P
	860814-17-1P	860814-18-2P	860814-19-3P
	860814-20-6P	860814-21-7P	860814-22-8P
	860814-23-9P	860814-24-0P	860814-25-1P
	860814-26-2P	860814-27-3P	860814-28-4P
	860814-29-5P	860814-30-8P	860814-31-9P
	860814-32-0P	860814-33-1P	860814-34-2P
	860814-35-3P	860814-36-4P	860814-37-5P
	860814-38-6P	860814-39-7P	860814-40-0P
	860814-41-1P	860814-42-2P	860814-43-3P
	860814-44-4P	860814-45-5P	860814-46-6P
	860814-47-7P	860814-48-8P	860814-49-9P
	860814-50-2P	860814-51-3P	860814-52-4P
	860814-53-5P	860814-54-6P	860814-55-7P
	860814-56-8P	860814-57-9P	860814-58-0P
	860814-59-1P	860814-60-4P	860814-61-5P
	860814-62-6P	860814-63-7P	860814-64-8P


860814-65-9P	860814-66-0P	860814-67-1P
860814-68-2P	860814-69-3P	860814-70-6P
860814-71-7P	860814-72-8P	860814-73-9P
860814-74-0P	860814-76-2P	860814-77-3P
860814-78-4P	860814-79-5P	860814-80-8P
860814-81-9P	860814-82-0P	860814-83-1P
860814-84-2P	860814-85-3P	860814-86-4P
860814-87-5P	860814-88-6P	860814-89-7P
860814-90-0P	860814-91-1P	860814-92-2P
860814-93-3P	860814-94-4P	860814-95-5P
860814-96-6P	860814-97-7P	916220-34-3P
916220-36-5P	916220-37-6P	916220-38-7P
916220-44-5P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of cyanopyrimidines useful in the treatment of cardiovascular diseases)


RN 860813-32-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-33-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-(phenylmethyl)-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-34-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-35-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-36-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.




RN 860813-37-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-38-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 860813-39-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 860813-40-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(propylamino)- (CA INDEX NAME)




RN 860813-41-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclopentylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-42-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-43-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-44-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-[(2-methoxyethyl)amino]-6-oxo- (CA INDEX NAME)




RN 860813-45-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-morpholinyl)-6-oxo- (CA INDEX NAME)




RN 860813-46-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo- (CA INDEX NAME)




RN 860813-47-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-[(2-methoxyphenyl)methyl]amino]-6-oxo- (CA INDEX NAME)




RN 860813-49-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-50-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-51-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-52-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperidinyl)-2-[(3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860813-53-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(propylamino)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-54-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-55-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-56-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-57-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-58-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-59-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-[4-(1,1-dimethylethyl)-1-piperidinyl]-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-60-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-61-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860813-62-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2-methoxyethyl)amino]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-63-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-64-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-65-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-67-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[(phenylmethyl)amino]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-68-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2-methoxyphenyl)methyl]amino]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-69-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-70-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-71-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-formyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-72-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4-acetyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-73-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4-ethyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-74-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclopropylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-75-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclohexylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860813-76-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860813-77-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-78-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-82-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-83-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-84-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860813-85-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-86-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-piperidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-87-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-4-(3-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)



RN 860813-88-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[3-(hydroxymethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-89-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-90-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[2-(hydroxymethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-91-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-92-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-93-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 860813-94-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(4-methylcyclohexyl)amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-95-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-[(4-(trifluoromethyl)cyclohexyl)amino]- (CA INDEX NAME)




RN 860813-96-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-97-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-pyrrolidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-98-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-99-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[(cyclopropylmethyl)amino]-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-00-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2R)-2-hydroxypropyl]amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-01-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methylamino]-1,6-dihydro-2-(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-02-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-2-(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-03-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-04-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 860814-05-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-06-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-07-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-08-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-10-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-12-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-piperidinyl)-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-13-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 860814-14-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 860814-15-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-16-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-17-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-18-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)



RN 860814-19-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-20-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)



RN 860814-21-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-22-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.



RN 860814-23-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-24-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-25-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860814-26-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860814-27-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[(4-pyridinylmethyl)amino]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-chlorophenyl)methyl]amino]-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-29-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3,5-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-30-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperidinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-31-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3,3-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-32-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperazinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-33-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(4-propyl-1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-34-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(1-oxobutyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-35-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(3-oxo-1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-36-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-morpholinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-37-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(2-pyridinylmethyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-38-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-39-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-40-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)


## Absolute stereochemistry.



RN 860814-41-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2-ethoxyphenyl)methyl]-

1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-42-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-43-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-44-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-45-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[[2-(6-methoxy-3-pyridinyl)phenyl]methyl]-6-oxo- (CA INDEX NAME)

## Absolute stereochemistry.




RN 860814-46-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-47-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-48-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)



RN 860814-49-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-50-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-51-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,6-dichlorophenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-52-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,6-dichlorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-53-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-[(2-methoxyethyl)methylamino]methyl]phenyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-54-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[[2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX NAME)



RN 860814-55-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[[2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 860814-56-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[[2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX)

NAME)




RN 860814-57-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-58-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-59-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-60-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-61-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-62-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-63-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-64-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-65-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)



RN 860814-66-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)



RN 860814-67-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[(2-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-68-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[ [2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 860814-69-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[ [2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 860814-70-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[ (2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[ (2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-71-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[ (2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-72-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-73-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-74-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-76-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-77-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-78-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-79-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[(2-trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 860814-80-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[(2-trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 860814-81-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-82-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 860814-83-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-84-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860814-85-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-86-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)



RN 860814-87-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-88-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-89-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-90-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-[(2-(phenylmethoxy)phenyl)methyl]-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860814-91-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[(2-(phenylmethoxy)phenyl)methyl]- (CA INDEX NAME)



RN 860814-92-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[2-(phenylmethoxy)phenyl]methyl- (CA INDEX NAME)



RN 860814-93-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[2-(phenylmethoxy)phenyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-94-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo-2-[2-(phenylmethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-95-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[2-(phenylmethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-96-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-[[2-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 860814-97-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[[2-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 916220-34-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)methyl]-4-(cyclobutylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 916220-36-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-4-[(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 916220-37-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 916220-38-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-4-[(4-hydroxy-1-piperidinyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)



RN 916220-44-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 2005:673271 CAPLUS  
 DN 143:172887  
 TI Preparation of 6-amino-5-cyano-pyrimidine-4-ones as phosphodiesterase 9A inhibitors for improving perception  
 IN Hendrix, Martin; Baerfacker, Lars; Heckroth, Heike; Karthaus, Dagmar; Tersteegen, Adrian  
 PA Bayer Healthcare A.-G., Germany  
 SO PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2

DT Patent  
 LA German

Applicant's

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005068436	A1	20050728	WO 2004-EP14872	20041231
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004001873	A1	20050929	DE 2004-102004001873	20040114
	AU 2004313696	A1	20050728	AU 2004-313696	20041231
	CA 2553200	A1	20050728	CA 2004-2553200	20041231
	EP 1709009	A1	20061011	EP 2004-804457	20041231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1926117	A	20070307	CN 2004-80042444	20041231
	BR 2004018407	A	20070515	BR 2004-18407	20041231
	JP 2007518726	T	20070712	JP 2006-548184	20041231
	MX 2006007982	A	20061019	MX 2006-7982	20060712
	IN 2006DN04026	A	20070817	IN 2006-DN4026	20060713
	ZA 2006005781	A	20080227	ZA 2006-5781	20060713
	KR 2007015372	A	20070202	KR 2006-716336	20060814
	US 20080255118	A1	20081016	US 2007-586501	20070914
PRAI	DE 2004-102004001873	A	20040114		
	WO 2004-EP14872	W	20041231		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 143:172887

AB Title compds. I [A = Ph, heteroaryl, etc.; R1 = (un)substituted cycloalkyl, alkyl, benzyl, etc.; R2 = H, R1 and R2 together with the N-atom to form a 5- or 6-membered heterocyclic ring] and their pharmaceutically acceptable salts were prepared. For example, condensation of piperidine and methylsulfanylpyrimidine II afforded cyanopyrimidinone III in 38% yield. In phosphodiesterase 9A (PDE9A) inhibition assays, 2-examples of compds. I exhibited IC50 values of 5 and 15 nM.

IT 860813-32-7P 860813-33-8P 860813-34-9P  
 860813-35-0P 860813-36-1P 860813-37-2P  
 860813-38-3P 860813-39-4P 860813-40-7P  
 860813-41-8P 860813-42-9P 860813-43-0P  
 860813-44-1P 860813-45-2P 860813-46-3P

860813-47-4P	860813-48-5P	860813-49-6P
860813-50-9P	860813-51-0P	860813-52-1P
860813-53-2P	860813-54-3P	860813-55-4P
860813-56-5P	860813-57-6P	860813-58-7P
860813-59-8P	860813-60-1P	860813-61-2P
860813-62-3P	860813-63-4P	860813-64-5P
860813-65-6P	860813-66-7P	860813-67-8P
860813-68-9P	860813-69-0P	860813-70-3P
860813-71-4P	860813-72-5P	860813-73-6P
860813-74-7P	860813-75-8P	860813-76-9P
860813-77-0P	860813-78-1P	860813-79-2P
860813-80-5P	860813-81-6P	860813-82-7P
860813-83-8P	860813-84-9P	860813-85-0P
860813-86-1P	860813-87-2P	860813-88-3P
860813-89-4P	860813-90-7P	860813-91-8P
860813-92-9P	860813-93-0P	860813-94-1P
860813-95-2P	860813-96-3P	860813-97-4P
860813-98-5P	860813-99-6P	860814-00-2P
860814-01-3P	860814-02-4P	860814-03-5P
860814-04-6P	860814-05-7P	860814-06-8P
860814-07-9P	860814-08-0P	860814-10-4P
860814-12-6P	860814-13-7P	860814-14-8P
860814-15-9P	860814-16-0P	860814-17-1P
860814-18-2P	860814-19-3P	860814-20-6P
860814-21-7P	860814-22-8P	860814-23-9P
860814-24-0P	860814-25-1P	860814-26-2P
860814-27-3P	860814-28-4P	860814-29-5P
860814-30-8P	860814-31-9P	860814-32-0P
860814-33-1P	860814-34-2P	860814-35-3P
860814-36-4P	860814-37-5P	860814-38-6P
860814-39-7P	860814-40-0P	860814-41-1P
860814-42-2P	860814-43-3P	860814-44-4P
860814-45-5P	860814-46-6P	860814-47-7P
860814-48-8P	860814-49-9P	860814-50-2P
860814-51-3P	860814-52-4P	860814-53-5P
860814-54-6P	860814-55-7P	860814-56-8P
860814-57-9P	860814-58-0P	860814-59-1P
860814-60-4P	860814-61-5P	860814-62-6P
860814-63-7P	860814-64-8P	860814-65-9P
860814-66-0P	860814-67-1P	860814-68-2P
860814-69-3P	860814-70-6P	860814-71-7P
860814-72-8P	860814-73-9P	860814-74-0P
860814-75-1P	860814-76-2P	860814-77-3P
860814-78-4P	860814-79-5P	860814-80-8P
860814-81-9P	860814-82-0P	860814-83-1P
860814-84-2P	860814-85-3P	860814-86-4P
860814-87-5P	860814-88-6P	860814-89-7P
860814-90-0P	860814-91-1P	860814-92-2P
860814-93-3P	860814-94-4P	860814-95-5P
860814-96-6P	860814-97-7P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminocyanopyrimidinones as phosphodiesterase 9A inhibitors for improving perception)

RN 860813-32-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-6-oxo-

4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-33-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-(phenylmethyl)-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-34-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-35-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-36-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-(3-methylphenyl)methyl-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860813-37-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2-hydroxyethyl)-1-piperidinyl]-2-(3-methylphenyl)methyl-6-oxo- (CA INDEX NAME)




RN 860813-38-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 860813-39-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 860813-40-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(propylamino)- (CA INDEX NAME)




RN 860813-41-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclopentylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-42-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 860813-43-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-44-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-[(2-methoxyethyl)amino]-6-oxo- (CA INDEX NAME)




RN 860813-45-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-morpholinyl)-6-oxo- (CA INDEX NAME)




RN 860813-46-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo- (CA INDEX NAME)




RN 860813-47-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-[(2-methoxyphenyl)methylamino]-6-oxo- (CA INDEX NAME)




RN 860813-48-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)methyl]-4-(cyclopropylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-49-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-50-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-51-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-52-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperidinyl)-2-[(3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860813-53-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(propylamino)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-54-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-55-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-56-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-57-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-58-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-59-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-[4-(1,1-dimethylethyl)-1-piperidinyl]-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-60-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-61-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860813-62-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2-methoxyethyl)amino]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-63-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-64-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-65-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-66-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-67-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[(phenylmethyl)amino]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-68-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2-methoxyphenyl)methyl]amino-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-69-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-70-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-71-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-formyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-72-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-acetyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860813-73-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4-ethyl-1-piperazinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860813-74-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclopropylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-75-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(cyclohexylamino)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-76-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860813-77-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-78-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-79-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)




RN 860813-80-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860813-81-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chlorophenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860813-82-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-83-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-84-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860813-85-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860813-86-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-piperidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-87-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-4-(3-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)



RN 860813-88-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[3-(hydroxymethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-89-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-90-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[2-(hydroxymethyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-91-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-92-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-93-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 860813-94-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(4-methylcyclohexyl)amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-95-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-[(4-(trifluoromethyl)cyclohexyl)amino]- (CA INDEX NAME)




RN 860813-96-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860813-97-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-pyrrolidinyl)-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860813-98-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860813-99-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[(cyclopropylmethyl)amino]-1,6-dihydro-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-00-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2R)-2-hydroxypropyl]amino]-2-[(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-01-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methylamino]-1,6-dihydro-2-(3-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-02-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-2-(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-03-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-04-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 860814-05-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-06-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-07-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-08-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-10-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-12-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(3-hydroxy-1-piperidinyl)-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-13-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 860814-14-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methylphenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 860814-15-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-16-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-17-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyano-1-piperidinyl)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-18-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860814-19-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-20-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)



RN 860814-21-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-22-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-fluorophenyl)methyl]-1,6-dihydro-4-[(trans-4-hydroxycyclohexyl)amino]-6-oxo- (CA INDEX NAME)

Relative stereochemistry.



RN 860814-23-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopropylamino)-2-[(2-fluorophenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-24-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

## Absolute stereochemistry.




RN 860814-25-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860814-26-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860814-27-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[(4-pyridinylmethyl)amino]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-chlorophenyl)methyl]amino]-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-29-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3,5-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-30-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-piperidinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-31-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3,3-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-32-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperazinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-33-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(4-propyl-1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-34-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(1-oxobutyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-35-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(3-oxo-1-piperazinyl)-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-36-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-morpholinyl)-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-37-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(2-pyridinylmethyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)




RN 860814-38-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-39-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-2-(3-thienylmethyl)- (CA INDEX NAME)



RN 860814-40-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-(3-thienylmethyl)- (CA INDEX NAME)


## Absolute stereochemistry.



RN 860814-41-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2-ethoxyphenyl)methyl]-

1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-42-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-43-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-2-[(2-ethoxyphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-44-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-45-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[[2-(6-methoxy-3-pyridinyl)phenyl]methyl]-6-oxo- (CA INDEX NAME)

## Absolute stereochemistry.




RN 860814-46-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-(6-methoxy-3-pyridinyl)phenyl)methyl]-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-47-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-48-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)



RN 860814-49-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-50-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-chlorophenyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-51-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,6-dichlorophenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-52-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-[(2,6-dichlorophenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-53-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-[(2-methoxyethyl)methylamino]methyl]phenyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-54-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX NAME)



RN 860814-55-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[(2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 860814-56-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[(2-[(2-methoxyethyl)methylamino]methyl]phenyl]methyl]-6-oxo- (CA INDEX)

NAME)




RN 860814-57-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-58-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-59-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-60-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860814-61-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2,3-dihydro-7-benzofuranyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-62-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-63-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-64-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-65-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperazinyl)-6-oxo-2-[2-(trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 860814-66-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)




RN 860814-67-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[(2-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-68-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[ [2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 860814-69-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[ [2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 860814-70-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[ (2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-[ (2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-71-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-2-[ (2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-72-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-2-[(2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-73-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 860814-74-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-75-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-2-[(2-methoxyphenyl)methyl]-6-oxo- (CA INDEX NAME)



RN 860814-76-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-77-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-4-(1-pyrrolidinyl)-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-78-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(4,4-dimethyl-1-piperidinyl)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)



RN 860814-79-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-80-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 860814-81-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[2-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)




RN 860814-82-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[2-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)




RN 860814-83-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo-4-(1-piperidinyl)- (CA INDEX NAME)




RN 860814-84-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo- (CA INDEX NAME)




RN 860814-85-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 860814-86-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo- (CA INDEX NAME)



RN 860814-87-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-88-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-89-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-2-[(2,5-dimethylphenyl)methyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 860814-90-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-[(2-phenylmethoxy)phenylmethyl]-4-(1-piperidinyl)- (CA INDEX NAME)



RN 860814-91-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-1,6-dihydro-6-oxo-2-[(2-phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 860814-92-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-1,6-dihydro-6-oxo-2-[(2-phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 860814-93-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-oxo-2-[(2-phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860814-94-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-methyl-1-piperidinyl)-6-oxo-2-[[2-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 860814-95-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-[4-(2-hydroxyethyl)-1-piperidinyl]-6-oxo-2-[[2-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 860814-96-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(4-hydroxy-1-piperidinyl)-6-oxo-2-[[2-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 860814-97-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-6-oxo-2-[(2-(phenylmethoxy)phenyl)methyl]- (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 2004:1154682 CAPLUS  
 DN 142:93840  
 TI Preparation of 6-arylamino-5-cyano-4-pyrimidinones as PDE9A inhibitors for  
 the treatment of Alzheimer's disease  
 IN Hendrix, Martin; Baerfacker, Lars; Beyreuther, Bettina; Ebert, Ulrich;  
 Erb, Christina; Hafner, Frank-Thorsten; Heckroth, Heike; Liu, Yan-Hong;  
 Schauss, Dagmar; Tersteegen, Adrian; Van Der Staay, Franz-Josef; Van  
 Kampen, Marja  
 PA Bayer Healthcare AG, Germany  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004113306	A1	20041229	WO 2004-EP6477	20040616
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10328479	A1	20050113	DE 2003-10328479	20030625
	AU 2004249392	A1	20041229	AU 2004-249392	20040616
	CA 2530461	A1	20041229	CA 2004-2530461	20040616
	EP 1644339	A1	20060412	EP 2004-739944	20040616
	EP 1644339	B1	20080123		
	R: DE, ES, FR, GB, IT				
	CN 1835929	A	20060920	CN 2004-80023392	20040616
	JP 2007506662	T	20070322	JP 2006-515952	20040616
	EP 1905765	A1	20080402	EP 2007-121390	20040616
	R: AT, DE, ES, FR, GB, IT				
	ES 2298769	T3	20080516	ES 2004-739944	20040616
	MX 2005013874	A	20060706	MX 2005-13874	20051216
	ZA 2005010319	A	20070328	ZA 2005-10319	20051220
	IN 2005DN05978	A	20091002	IN 2005-DN5978	20051221
	US 20070105881	A1	20070510	US 2006-559954	20060928
	US 7488733	B2	20090210		
	US 20090111838	A1	20090430	US 2008-339393	20081219
PRAI	DE 2003-10328479	A	20030625		
	EP 2004-739944	A3	20040616		
	WO 2004-EP6477	W	20040616		
	US 2006-559954	A1	20060928		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 142:93840

AB Title compds. I [A = (un)substituted alkyl, cycloalkyl, tetrahydrofuryl,  
 etc.; B = (un)substituted Ph, heteroaryl] and their pharmaceutically  
 acceptable salts were prepared. For example, condensation-cyclization of  
 1-cyclopentylacetamidine hydrochloride and (methylsulfanyl)propenoate II,  
 e.g., prepared from 4-fluoroaniline and Me

3,3-bis(methylthio)-2-cyanoacrylate, afforded cyanopyrimidinone III in 46% yield. In phosphodiesterase 9A (PDE9A) inhibition assays, 5-examples of compds. I exhibited IC<sub>50</sub> values ranging from 52-87 nM, e.g., the IC<sub>50</sub> value of cyanopyrimidinone III was 75 nM. Compds. I are claimed to be useful for the treatment of Alzheimer's disease.


IT	816468-96-9P	816468-97-0P	816468-98-1P
	816468-99-2P	816469-00-8P	816469-01-9P
	816469-02-0P	816469-03-1P	816469-04-2P
	816469-05-3P	816469-06-4P	816469-07-5P
	816469-08-6P	816469-12-2P	816469-13-3P
	816469-14-4P	816469-15-5P	816469-16-6P
	816469-17-7P	816469-18-8P	816469-19-9P
	816469-20-2P	816469-21-3P	816469-24-6P
	816469-25-7P	816469-26-8P	816469-27-9P
	816469-28-0P	816469-29-1P	816469-30-4P
	816469-31-5P	816469-32-6P	816469-33-7P
	816469-34-8P	816469-35-9P	816469-36-0P
	816469-37-1P	816469-39-3P	816469-40-6P
	816469-41-7P	816469-42-8P	816469-43-9P
	816469-44-0P	816469-45-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylaminocyanopyrimidinones as PDE9A inhibitors for the treatment of Alzheimer's disease)

RN 816468-96-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(4-fluorophenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)



claimed compounds require that A is aryl or heteroaryl


RN 816468-97-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(4-methyl-3-pyridinyl)amino]-6-oxo- (CA INDEX NAME)




RN 816468-98-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,6-dihydro-4-[(4-methyl-3-pyridinyl)amino]-6-oxo- (CA INDEX NAME)




RN 816468-99-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(3-fluorophenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-00-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-[(3-chlorophenyl)amino]-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-01-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(3-methoxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-02-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(3-fluoro-2-methylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-03-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(2,5-dimethylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-04-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methoxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-05-3 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(4-fluoro-2-methylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-06-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 816469-07-5 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-[(2-propylphenyl)amino]- (CA INDEX NAME)




RN 816469-08-6 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 816469-12-2 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(2-fluorophenyl)amino]-

1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-13-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2-chlorophenyl)amino]-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-14-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-(phenylamino)- (CA INDEX NAME)




RN 816469-15-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methyl-3-pyridinyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-16-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-hydroxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-17-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(5-fluoro-2-methylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-18-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-[(3-(trifluoromethyl)phenyl)amino]- (CA INDEX NAME)




RN 816469-19-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(4-(dimethylamino)phenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-20-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(4-methoxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-21-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(4-methylphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-24-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-4-[(2-fluorophenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-25-7 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-4-[(5-fluoro-2-methylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-26-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-4-[(3-fluoro-2-methylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 816469-27-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-[(2-chlorophenyl)amino]-2-(cyclohexylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-28-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,6-dihydro-6-oxo-4-(phenylamino)- (CA INDEX NAME)




RN 816469-29-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,6-dihydro-4-[(2-methoxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-30-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,6-dihydro-4-[(2-methylphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-31-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[(5-acetyl-2-methyl-3-thienyl)amino]-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 816469-32-6 CAPLUS  
 CN 3-Thiophenecarboxylic acid, 4-[(5-cyano-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]-, methyl ester (CA INDEX NAME)




RN 816469-33-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-[(2-cyano-3-thienyl)amino]-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-34-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(2-cyclopenten-1-ylmethyl)-1,6-dihydro-4-[(2-

methylphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-35-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(2-cyclopenten-1-ylmethyl)-4-[(2-fluorophenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-36-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2-chlorophenyl)amino]-2-(2-cyclopenten-1-ylmethyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-37-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(2-cyclopenten-1-ylmethyl)-1,6-dihydro-4-[(2-methoxyphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-39-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methoxy-4-methylphenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-40-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(2,3-dimethylphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-41-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-(1-methylethyl)phenyl)amino]-6-oxo- (CA INDEX NAME)




RN 816469-42-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(2,4-dimethoxyphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 816469-43-9 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methoxy-5-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 816469-44-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-4-[(2,5-dimethoxyphenyl)amino]-1,6-dihydro-6-oxo- (CA INDEX NAME)



RN 816469-45-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,6-dihydro-4-[(2-methoxy-6-methylphenyl)amino]-6-oxo- (CA INDEX NAME)




OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/586,501

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 1988:150414 CAPLUS  
 DN 108:150414  
 OREF 108:24701a,24704a  
 TI Chemistry and positive inotropic effect of pelrinone and related derivatives. A novel class of 2-methylpyrimidones as inotropic agents  
 AU Bagli, Jehan; Bogri, T.; Palameta, B.; Rakhit, S.; Peseckis, S.; McQuillan, J.; Lee, D. K. H.  
 CS Ayerst Lab. Res., Inc., Princeton, NJ, 08543-9990, USA  
 SO Journal of Medicinal Chemistry (1988), 31(4), 814-23  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 OS CASREACT 108:150414  
 AB Novel pyrimidine derivs. (e.g., I; R = cyano, R1 = 3-pyridylmethyl) were synthesized and evaluated for pos. inotropic activity. Thus, (MeS)2C:C(CN)CO2Me cyclocondensed with MeC(:NH)NH2·HCl to give cyano methyl(methythio)dihydropyrimidinone II, which was treated with 3-(aminomethyl)pyridine to give 48% I (R = cyano, R1 = 3-pyridylmethyl). Inotropic and chronotropic effects were determined in vitro in cat papillary muscle and right atrium, resp. Selected compds. were then evaluated in vivo in a dog heart failure model. Changes in ventricular dP/dt, heart rate, and blood pressure were monitored. Several of these agents produced relatively minor changes in heart rate. This class of agents demonstrated a varying degree of vasodilator effects concomitant with increases in ventricular contractility. The most potent analogs, I (R = cyano, R1 = 3-pyridylmethyl; R = Br, R1 = Et, 3-pyridylmethyl), were evaluated orally in conscious dogs with implanted Konisberg pressure transducers, and their effect on left ventricular dP/dt was compared with that of milrinone. Mechanistically, the agents of this novel class appear not to mediate their effect either via  $\beta$ -receptors or inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase. A major component of their inotropic effect is mediated by the inhibition of cardiac phosphodiesterase (PDE)-Fr. III. This was clearly demonstrated by I. Compound I (R = Br, R1 = 3-pyridylmethyl) was found to be the most potent inhibitor of PDE-Fr. III from among the compds. tested in this assay. The crystal structure of I (R = cyano, 3-pyridylmethyl)·HBF<sub>4</sub> is also reported.  
 IT 96824-01-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and cardiotonic activity of)  
 RN 96824-01-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-(phenylmethyl)-4-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



102(b)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
 AN 1985:406358 CAPLUS  
 DN 103:6358  
 OREF 103:1147a,1150a  
 TI Amino-pyrimidine derivatives  
 IN Bagli, Jehan Framoz  
 PA American Home Products Corp., USA  
 SO Eur. Pat. Appl., 50 pp.  
 CODEN: EPXXDW

same as # 4

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 130735	A1	19850109	EP 1984-304158	19840620
	EP 130735	B1	19881102		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4505910	A	19850319	US 1983-509886	19830630
	US 4507304	A	19850326	US 1983-509887	19830630
	ZA 8404476	A	19860226	ZA 1984-4476	19840613
	AT 38328	T	19881115	AT 1984-304158	19840620
	AU 8429710	A	19850103	AU 1984-29710	19840621
	AU 572856	B2	19880519		
	HU 34465	A2	19850328	HU 1984-2441	19840622
	HU 193581	B	19871028		
	DK 8403090	A	19841231	DK 1984-3090	19840625
	JP 60025974	A	19850208	JP 1984-131827	19840625
	CA 1232905	A1	19880216	CA 1984-457551	19840627
	CA 1248104	A2	19890103	CA 1986-505828	19860403
PRAI	US 1983-509886	A	19830630		
	US 1983-509887	A	19830630		
	EP 1984-304158	A	19840620		
	CA 1984-457551	A3	19840627		

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 103:6358

AB Title derivs. I [X = O, S, NH; R = alkyl, cycloalkyl, phenylalkyl, CF<sub>3</sub>; R<sub>1</sub> = CN, CONH<sub>2</sub>, NO<sub>2</sub>, SO<sub>2</sub>Me, SO<sub>2</sub>NH<sub>2</sub>; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> = H, alkyl; R<sub>7</sub> = H, alkenyl, piperidino, 1-pyrrolidinyl, 1-piperazinyl, furyl, indolyl, thienyl, etc.; m, n = 0, 1, 2] were prepared as cardiotonic agents. Thus, the cyclocondensation of MeC(:NH)NH<sub>2</sub>.HCl with (MeS)2C:C(CN)CO<sub>2</sub>Me in DMF containing NaH gave pyrimidine II, which was treated with 3-(aminomethyl)pyridine to give aminopyrimidine III. III at 10-4 M increased contractility by 98% in isolated cat papillary muscle.

IT 96824-01-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 96824-01-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-6-oxo-2-(phenylmethyl)-4-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

10/586,501

=>

=> log y

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	42.55	236.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.25	-4.25

STN INTERNATIONAL LOGOFF AT 17:22:31 ON 11 APR 2010